Lung cancer combination therapy: doxorubicin and β-elemene co-loaded, pH-sensitive nanostructured lipid carriers

References

• Torre LA, Siegel RL, Jemal A. Lung cancer statistics. Adv Exp Med Biol. 2016;893:1–19. doi:10.1007/978-3-319-24223-1_126667336
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30. doi:10.3322/caac.2144229313949
   PubMed Web of Science ®Google Scholar
• Wakelee H, Kelly K, Edelman MJ. 50 years of progress in the systemic therapy of non-small cell lung cancer. Am Soc Clin Oncol Educ Book. 2014;177–189. doi:10.14694/EdBook_AM.2014.34.17724857075
   PubMedGoogle Scholar
• Pérez-Herrero E, Fernández-Medarde A. Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm. 2015;93:52–79. doi:10.1016/j.ejpb.2015.03.01825813885
   PubMed Web of Science ®Google Scholar
• Lee MS, Dees EC, Wang AZ. Nanoparticle-delivered chemotherapy: old drugs in new packages. Oncology (Williston Park). 2017;31(3):198–208.28299757
   PubMed Web of Science ®Google Scholar
• Estanqueiro M, Amaral MH, Conceição J, Sousa Lobo JM. Nanotechnological carriers for cancer chemotherapy: the state of the art. Colloids Surf B Biointerfaces. 2015;126:631–648. doi:10.1016/j.colsurfb.2014.12.04125591851
   PubMed Web of Science ®Google Scholar
• Madane RG, Mahajan HS. Curcumin-loaded nanostructured lipid carriers (NLCs) for nasal administration: design, characterization, and in vivo study. Drug Deliv. 2016;23(4):1326–1334. doi:10.3109/10717544.2014.97538225367836
   PubMed Web of Science ®Google Scholar
• Song S, Mao G, Du J, Zhu X. Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy. Drug Deliv. 2016;23(4):1404–1408. doi:10.3109/10717544.2015.106418626203687
   PubMed Web of Science ®Google Scholar
• Muller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev. 2002;54(Suppl 1):S131–155.12460720
   PubMed Web of Science ®Google Scholar
• Liu Q, Li J, Pu G, Zhang F, Liu H, Zhang Y. Co-delivery of baicalein and doxorubicin by hyaluronic acid decorated nanostructured lipid carriers for breast cancer therapy. Drug Deliv. 2016;23(4):1364–1368. doi:10.3109/10717544.2015.103129525874959
   PubMed Web of Science ®Google Scholar
• Du J, Li L. Which one performs better for targeted lung cancer combination therapy: pre- or post-bombesin-decorated nanostructured lipid carriers? Drug Deliv. 2016;23(5):1799–1809. doi:10.3109/10717544.2015.109905826455787
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang H, Hao J, Li B, Li M, Xiuwen W. Lung cancer combination therapy: co-delivery of paclitaxel and doxorubicin by nanostructured lipid carriers for synergistic effect. Drug Deliv. 2016;23(4):1398–1403. doi:10.3109/10717544.2015.105561926079530
   PubMed Web of Science ®Google Scholar
• Taratula O, Kuzmov A, Shah M, Garbuzenko OB, Minko T. Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA. J Control Release. 2013;171(3):349–357. doi:10.1016/j.jconrel.2013.04.01823648833
   PubMed Web of Science ®Google Scholar
• Tan S, Wang G. Redox-responsive and pH-sensitive nanoparticles enhanced stability and anticancer ability of erlotinib to treat lung cancer in vivo. Drug Des Devel Ther. 2017;11:3519–3529. doi:10.2147/DDDT.S151422
   PubMed Web of Science ®Google Scholar
• Tran TH, Ramasamy T, Choi JY, et al. Tumor-targeting, pH-sensitive nanoparticles for docetaxel delivery to drug-resistant cancer cells. Int J Nanomedicine. 2015;10:5249–5262. doi:10.2147/IJN.S8958426346426
   PubMed Web of Science ®Google Scholar
• Wang B, Peng XX, Sun R, et al. Systematic review of β-elemene injection as adjunctive treatment for lung cancer. Chin J Integr Med. 2012;18(11):813–823. doi:10.1007/s11655-012-1271-923086485
   PubMed Web of Science ®Google Scholar
• Zhai B, Zeng Y, Zeng Z, et al. Drug delivery systems for elemene, its main active ingredient β-elemene, and its derivatives in cancer therapy. Int J Nanomedicine. 2018;13:6279–6296. doi:10.2147/IJN.S17452730349250
   PubMed Web of Science ®Google Scholar
• Liu Y, Jiang ZY, Zhou YL, et al. β-elemene regulates endoplasmic reticulum stress to induce the apoptosis of NSCLC cells through PERK/IRE1α/ATF6 pathway. Biomed Pharmacother. 2017;93:490–497. doi:10.1016/j.biopha.2017.06.07328672279
   PubMed Web of Science ®Google Scholar
• Li J, JunYu LA, Wang Y. β-elemene against human lung cancer via up-regulation of P53 protein expression to promote the release of exosome. Lung Cancer. 2014;86(2):144–150. doi:10.1016/j.lungcan.2014.08.01525204604
   PubMed Web of Science ®Google Scholar
• Lin L, Li L, Chen X, Zeng B, Lin T. Preliminary evaluation of the potential role of β-elemene in reversing erlotinib-resistant human NSCLC A549/ER cells. Oncol Lett. 2018;16(3):3380–3388. doi:10.3892/ol.2018.898030127938
   PubMed Web of Science ®Google Scholar
• Manh Hung LV, Song YW, Cho SK. Effects of the combination of gliotoxin and adriamycin on the adriamycin-resistant non-small-cell lung cancer A549 cell line. Mar Drugs. 2018;16(4). doi:10.3390/md16040105
   PubMed Web of Science ®Google Scholar
• Cai Z, Zhang H, Wei Y, Wei Y, Xie Y, Cong F. Reduction- and pH-sensitive hyaluronan nanoparticles for delivery of iridium(III) anticancer drugs. Biomacromolecules. 2017;18(7):2102–2117. doi:10.1021/acs.biomac.7b0044528605176
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang P, Zhu T. Ovarian carcinoma biological nanotherapy: comparison of the advantages and drawbacks of lipid, polymeric, and hybrid nanoparticles for cisplatin delivery. Biomed Pharmacother. 2018;3(109):475–483.
   Google Scholar
• Shi F, Yang G, Ren J, Guo T, Du Y, Feng N. Formulation design, preparation, and in vitro and in vivo characterizations of β-elemene-loaded nanostructured lipid carriers. Int J Nanomedicine. 2013;8:2533–2541. doi:10.2147/IJN.S4657823901271
   PubMed Web of Science ®Google Scholar
• Cui T, Zhang S, Sun H. Co-delivery of doxorubicin and pH-sensitive curcumin prodrug by transferrin-targeted nanoparticles for breast cancer treatment. Oncol Rep. 2017;37(2):1253–1260. doi:10.3892/or.2017.534528075466
   PubMed Web of Science ®Google Scholar
• Qiu J, Cai G, Liu X, Ma D. α(v)β(3) integrin receptor specific peptide modified, salvianolic acid B and panax notoginsenoside loaded nanomedicine for the combination therapy of acute myocardial ischemia. Biomed Pharmacother. 2017;96:1418–1426. doi:10.1016/j.biopha.2017.10.08629079344
   PubMed Web of Science ®Google Scholar
• Li S, Wang L, Li N, Liu Y, Su H. Combination lung cancer chemotherapy: design of a pH-sensitive transferrin-PEG-Hz-lipid conjugate for the co-delivery of docetaxel and baicalin. Biomed Pharmacother. 2017;95:548–555. doi:10.1016/j.biopha.2017.08.09028869892
   PubMed Web of Science ®Google Scholar
• Li C, Li H, Wang Q, et al. pH-sensitive polymeric micelles for targeted delivery to inflamed joints. J Control Release. 2017;246:133–141. doi:10.1016/j.jconrel.2016.12.02728038947
   PubMed Web of Science ®Google Scholar
• Yan J, Wang Y, Jia Y, et al. Co-delivery of docetaxel and curcumin prodrug via dual-targeted nanoparticles with synergistic antitumor activity against prostate cancer. Biomed Pharmacother. 2017;88:374–383. doi:10.1016/j.biopha.2016.12.13828122302
   PubMed Web of Science ®Google Scholar
• Zhang J, Xiao X, Zhu J, et al. Lactoferrin- and RGD-comodified, temozolomide and vincristine-coloaded nanostructured lipid carriers for gliomatosis cerebri combination therapy. Int J Nanomedicine. 2018;13:3039–3051. doi:10.2147/IJN.S16116329861635
   PubMed Web of Science ®Google Scholar
• Tan S, Wang G. Lung cancer targeted therapy: folate and transferrin dual targeted, glutathione responsive nanocarriers for the delivery of cisplatin. Biomed Pharmacother. 2018;102:55–63. doi:10.1016/j.biopha.2018.03.04629549729
   PubMed Web of Science ®Google Scholar
• Wang Z, Wei Y, Fang G, et al. Colorectal cancer combination therapy using drug and gene co-delivered, targeted poly(ethylene glycol)-ε-poly(caprolactone) nanocarriers. Drug Des Devel Ther. 2018;12:3171–3180. doi:10.2147/DDDT.S175614
   PubMed Web of Science ®Google Scholar
• Nie Y, Günther M, Gu Z, Wagner E. Pyridylhydrazone-based PEGylation for pH-reversible lipopolyplex shielding. Biomaterials. 2011;32(3):858–869. doi:10.1016/j.biomaterials.2010.09.03221030074
   PubMed Web of Science ®Google Scholar
• Jelezova I, Drakalska E, Momekova D, et al. Curcumin loaded pH-sensitive hybrid lipid/block copolymer nanosized drug delivery systems. Eur J Pharm Sci. 2015;78:67–78. doi:10.1016/j.ejps.2015.07.00526159739
   PubMed Web of Science ®Google Scholar
• Yu D, Li W, Zhang Y, Zhang B. Anti-tumor efficiency of paclitaxel and DNA when co-delivered by pH responsive ligand modified nanocarriers for breast cancer treatment. Biomed Pharmacother. 2016;83:1428–1435. doi:10.1016/j.biopha.2016.08.06127592131
   PubMed Web of Science ®Google Scholar
• Yan J, Wang Y, Zhang X, Liu S, Tian C, Wang H. Targeted nanomedicine for prostate cancer therapy: docetaxel and curcumin co-encapsulated lipid-polymer hybrid nanoparticles for the enhanced anti-tumor activity in vitro and in vivo. Drug Deliv. 2016;23(5):1757–1762. doi:10.3109/10717544.2015.106942326203689
   PubMed Web of Science ®Google Scholar
• Liang Y, Tian B, Zhang J, et al. Tumor-targeted polymeric nanostructured lipid carriers with precise ratiometric control over dual-drug loading for combination therapy in non-small-cell lung cancer. Int J Nanomedicine. 2017;12:1699–1715. doi:10.2147/IJN.S12126228280336
   PubMed Web of Science ®Google Scholar
• Dong T, Chen N, Ma X, et al. The protective roles of L-borneolum, D-borneolum and synthetic borneol in cerebral ischaemia via modulation of the neurovascular unit. Biomed Pharmacother. 2018;102:874–883. doi:10.1016/j.biopha.2018.03.08729728011
   PubMed Web of Science ®Google Scholar
• Fang XB, Zhang JM, Xie X, et al. pH-sensitive micelles based on acid-labile pluronic F68-curcumin conjugates for improved tumor intracellular drug delivery. Int J Pharm. 2016;502(1–2):28–37. doi:10.1016/j.ijpharm.2016.01.02926784981
   PubMed Web of Science ®Google Scholar
• Baek JS, Cho CW. A multifunctional lipid nanoparticle for co-delivery of paclitaxel and curcumin for targeted delivery and enhanced cytotoxicity in multidrug resistant breast cancer cells. Oncotarget. 2017;8(18):30369–30382. doi:10.18632/oncotarget.1615328423731
   PubMedGoogle Scholar
• Liu J, Cheng H, Han L, et al. Synergistic combination therapy of lung cancer using paclitaxel- and triptolide-coloaded lipid-polymer hybrid nanoparticles. Drug Des Devel Ther. 2018;12:3199–3209. doi:10.2147/DDDT.S172199
   PubMed Web of Science ®Google Scholar
• Wang G, Wang Z, Li C, et al. RGD peptide-modified, paclitaxel prodrug-based, dual-drugs loaded, and redox-sensitive lipid-polymer nanoparticles for the enhanced lung cancer therapy. Biomed Pharmacother. 2018;106:275–284. doi:10.1016/j.biopha.2018.06.13729966971
   PubMed Web of Science ®Google Scholar
• Ding Y, Sun D, Wang GL, et al. An efficient PEGylated liposomal nanocarrier containing cell-penetrating peptide and pH-sensitive hydrazone bond for enhancing tumor-targeted drug delivery. Int J Nanomedicine. 2015;10:6199–6214. doi:10.2147/IJN.S9251926491292
   PubMed Web of Science ®Google Scholar